Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Enzyme Deficiency Improves Clinical Picture in Mouse Model of Gaucher's Disease

By BiotechDaily International staff writers
Posted on 10 Feb 2014
Image: Elevation of RIPK3 in nuclei of neurons (red; arrows) from neuronopathic Gaucher's disease mice (Photo courtesy of Dr. Anthony Futerman, Weizmann Institute of Science).
Image: Elevation of RIPK3 in nuclei of neurons (red; arrows) from neuronopathic Gaucher's disease mice (Photo courtesy of Dr. Anthony Futerman, Weizmann Institute of Science).
Blocking the activity of a specific enzyme reversed the clinical symptoms of Gaucher's disease (GD) in a mouse model of this hereditary lipid storage disease.

GD is a hereditary disease caused by a recessive mutation in a gene located on chromosome 1 that causes a deficiency of the enzyme glucocerebrosidase. This enzyme acts on the fatty acid glucosylceramide, and when the enzyme is defective, glucosylceramide accumulates, particularly in white blood cells, most often macrophages. Glucosylceramide can also collect in the spleen, liver, kidneys, lungs, brain, and bone marrow. Clinical manifestations may include enlarged spleen and liver, liver malfunction, skeletal disorders and bone lesions that may be painful, severe neurological complications, swelling of lymph nodes, distended abdomen, a brownish tint to the skin, anemia, low blood platelets and yellow fatty deposits on the white of the eye.

Investigators at the Weizmann Institute of Science (Rehovot, Israel) examined the role of the enzyme Ripk3 (receptor-interacting serine-threonine-protein kinase 3) in GD. Ripk3, the product of the RIPK3 gene, is predominantly localized to the cytoplasm, and can undergo nucleocytoplasmic shuttling dependent on novel nuclear localization and export signals. It is a component of the tumor necrosis factor (TNF) receptor-I signaling complex, and can induce apoptosis and weakly activate the transcription factor NF-kappaB.

To study the relationship between Ripk3 and GD the investigators used a GD mouse model that included animals with and without active Ripk3. Results published in the January 19, 2014, online edition of the journal Nature Medicine revealed that Ripk3 deficiency substantially improved the clinical course of GD in the mice, with increased survival and motor coordination and salutary effects on cerebral as well as hepatic injury. Furthermore, the lifespan of these mice was remarkably increased, from approximately 35 days to more than 170 days.

“If successful, the new target could be used as either a complementary or alternative therapy for Gaucher's disease, and with RIPK3 proving to be a "hot" cellular pathway in various pathologies, these results may also have implications in other neurodegenerative diseases, including related diseases such as Krabbe disease, and potentially other devastating brain diseases,” said senior author Dr. Anthony Futerman, professor of biological chemistry at the Weizmann Institute of Science.

Related Links:

Weizmann Institute of Science
 


BIOSIGMA S.R.L.
RANDOX LABORATORIES
SLAS - Society for Laboratory Automation and Screening
comments powered by Disqus

Channels

Drug Discovery

view channel

Omega 3 Found to Improve Behavior in Children with ADHD

Supplements of the fatty acids omega 3 and 6 can help children and adolescents who have a specific kind of have attention deficit hyperactivity disorder (ADHD). Moreover, these findings indicate that a customized cognitive training program can improve problem behavior in children with ADHD. Statistics show that 3%–6%... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel

e-Incubator Technology Provides Real-Time Imaging of Bioengineered Tissues in a Controlled Unit

A new e-incubator, an innovative miniature incubator that is compatible with magnetic resonance imaging (MRI), enables scientists to grow tissue-engineered constructs under a controlled setting and to study their growth and development in real time without risk of contamination or damage. Offering the potential to test... Read more

Business

view channel

Two Industry Partnerships Initiated to Fuel Neuroscience Research

Faster, more complex neural research is now attainable by combining technology from two research companies. Blackrock Microsystems, LLC (Salt Lake City, UT, USA), a developer of neuroscience research equipment, announced partnerships with two neuroscience research firms—PhenoSys, GmbH (Berlin, Germany) and NAN Instruments, Ltd.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.